Sermorelin (sermorelin acetate, Geref)
Sermorelin: What The Studies Actually Say
It was a real FDA-approved drug for children who lacked growth hormone, until both approvals ended in 2009. The adult anti-aging claims rest on a few small, short studies that mostly measured hormones.
Updated 22 September 2026
Before you read this
This page explains what published studies found. That is all it is. It is not medical advice, and it is not instructions for using anything. Nothing here is meant to find, treat, cure or stop any illness. The compounds discussed on this site, retatrutide included, are not approved by the FDA for use in people. Research compounds are sold for laboratory use only — not for use in humans or animals. A study tells you what happened to the people in it. It does not tell you what would happen to you. What you do with what you read here is your responsibility, so talk to a doctor first. This page is published by Ascend Vials, which sells research compounds.
Read the full guide
Confirm you have read the notice above and enter an email address. We will send you a link back to this guide, and sometimes an email when we publish a new one. You can unsubscribe any time.
Sermorelin is not a new peptide. It was a real medicine called Geref, and the FDA approved it twice in the 1990s: as a test of the pituitary gland, and as a treatment for children. Federal Register, 2013
Both approvals ended in 2009. Neither ever covered treating adults. Yet most of what you hear about sermorelin today is about adults.
Here is what the research found, for children and for adults. Every claim has a link. Read them yourself.
The 30-second version
- Sermorelin copies part of GHRH, the body's signal to release growth hormone. It is not growth hormone.
- It was FDA-approved as a pituitary test and to treat children who lacked growth hormone. Both approvals ended in 2009 at the maker's request. FDA found that was not for safety or effectiveness reasons.
- In the biggest study, children's growth rate nearly doubled, but there was no comparison group. Next to real growth hormone, it never came out ahead.
- In one trial, 39 of 40 children made antibodies against it. In some, the effect faded.
- In older adults, small studies of 2 weeks to 6 months showed it raises growth hormone, and in most, IGF-1. Muscle and fat results are mixed. Sleep got slightly worse. Nobody measured falls, disease or lifespan.
- No approval ever covered adults or anti-aging. No approved version exists in the US today. It is banned in sport.
- Nothing sold online has been shown to match what the studies used. No study has checked.
What it is
Sermorelin is a lab-made peptide: a chain of 29 building blocks called amino acids. It copies the first 29 of the 44 in GHRH, growth hormone-releasing hormone, which the body makes on its own. US label
It is a signal, not a hormone replacement. It tells the pituitary gland to release the body's own growth hormone, which then pushes up a second hormone, IGF-1. US label · Review, 1999
It is gone from the blood within minutes. Yet the growth hormone it releases peaks at about 30 minutes and lasts 2 to 3 hours. Irish label
The numbers, from the main study
The biggest study treated 110 children who had not reached puberty and whose bodies did not make enough growth hormone. They got one shot a day for up to a year. 86 counted in the final results. There was no comparison group. Each child was compared with their own growth before treatment. JCEM, 1996
At 6 months, 74% were judged to have responded well. Their bones did not mature faster than their height grew. Blood sugar did not change, and IGF-1 did not go too high. JCEM, 1996
How it compares with real growth hormone
| Study | Children | Sermorelin | Growth hormone |
|---|---|---|---|
| Randomized, 6 months | 60 | 9.2 to 9.3 cm a year | 14.6 cm a year |
| Randomized, 6 months | 43 | Higher dose kept pace, lower dose slowest | Only group better on height for bone age |
| Sermorelin 1 year, then growth hormone | 9 | 6.0 cm a year, up from 3.3 | 7.5 cm a year |
| Sermorelin 6+ months, then growth hormone | 7 | 5 of 7 did not grow better | All grew better, average 8.5 cm a year |
Read the whole table. Sermorelin never beat growth hormone in any of these studies.
The first trial is the cleanest test: 60 children split into three groups by chance. Its abstract says sermorelin was given nonstop, by infusion. IGF-1 rose at first on sermorelin, then fell back to where it started. Acta Paediatrica, 1993 The last two rows are not fair head-to-heads: the same children took sermorelin first and growth hormone after. Clin Endocrinol, 1997 · Eur J Pediatr, 1989
Why the effect can fade
Antibodies. In that 60-child trial, 39 of 40 children on sermorelin made antibodies against it. They did not track with growth, and had almost disappeared 9 months after stopping. Acta Paediatrica, 1993
The response wears down. Six children got it as a nonstop infusion under the skin for 6 months. Their growth hormone output more than doubled, then slid back almost to where it started. By the end, one child's growth hormone was completely shut off, and 3 of the 6 had not grown significantly. Acta Paediatrica, 1993 In 18 short children with normal growth hormone, a year of shots raised growth from 4.8 to 7.2 cm a year, but their own night-time growth hormone fell. After stopping, growth dipped below the old rate for 3 months. Clin Endocrinol, 1994
The body keeps its brakes. In 6 healthy men, growth hormone given 3 hours earlier wiped out the response to sermorelin. Source, 1987 In lab cells, the receptor sermorelin switches on went quiet fast after brief exposure. Source, 2001
In adults, most studies measured hormones
This is where today's claims live, and where the evidence is thinnest. In 2003, the team behind the biggest adult trials wrote that every published study of GHRH in normal aging had been small and focused on in-between measures. Review, 2003
- 14 days, 10 men averaging 68. The higher of two doses brought growth hormone and IGF-1 up to the level of young men. There was no fake shot, and it measured hormones only. JCEM, 1992
- 6 weeks, 11 men aged 64 to 76. Night-time growth hormone rose, but IGF-1 did not. 2 of 6 strength tests improved. Weight, muscle and fat on a body scan did not change. No comparison group. Metabolism, 1997
- 5 to 6 months, the Seattle trials, against a fake shot. Men's growth hormone doubled and IGF-1 rose about 40%. In women on estrogen pills, IGF-1 rose under 10%. Body fat fell about 5% in men and in women not on estrogen, with a matching rise in lean mass. The authors called these results preliminary. Seattle report, 2001
- 6 months, 89 adults averaging 68, against a fake shot. Scores on several thinking tests improved. The summary says only "GHRH"; the team's earlier report says its trials used sermorelin. It did not look at dementia or daily life. Neurobiol Aging, 2006
None of them measured falls, broken bones, frailty, disease or death. Review, 2003
Sleep got slightly worse. In the Seattle trials, people on sermorelin rated their sleep a little worse: their score rose from 4.1 to 5.41, where higher is worse. On the fake shot it barely moved, from 4.51 to 4.61. Seattle report, 2001
Two studies that are not quite sermorelin. A 16-week trial in 19 older adults used a close relative, [Nle27]GHRH(1-29)-NH2. Lean mass improved in men only. JCEM, 1997 And a look back at 14 men's records found IGF-1 rose from 159.5 to 239.0 ng/mL, but they took sermorelin mixed with two other peptides. Am J Mens Health, 2017
The long-life claim points the other way
No study shows sermorelin helps people or animals live longer. The closest animal studies point the other way.
Mice bred without the gene for GHRH, the hormone sermorelin copies, lived a median 46% longer: 931 days against 636. eLife, 2013 Fast-aging mice given a drug that blocks GHRH lived 8 weeks longer on average, with fewer tumors. PNAS, 2010
In a lab, full-length GHRH made non-cancerous human prostate cells grow faster, and only those cells formed tumors in mice. That was not sermorelin, and not people. Prostate, 2022
What to expect
The US label lists these from clinical trials. US label
| From the US label | How often |
|---|---|
| Pain, swelling or redness where the shot went in | About 1 in 6 |
| Stopped because of shot reactions | 3 of 350 people |
| Headache, flushing, trouble swallowing, dizziness, hyperactivity, sleepiness, hives | Under 1% each |
| Underactive thyroid during treatment | 6.5% |
| Antibodies against sermorelin | "A large proportion," meaning unclear |
The label says an underactive thyroid can weaken the response, and steroid medicines called glucocorticoids may block it. No long-term animal studies of cancer or fertility were ever done. US label The Irish label says it must not be used in pregnancy or breastfeeding. Irish label
Other studies add:
- In the 18 short children, fasting blood sugar and insulin rose during treatment. Clin Endocrinol, 1994
- In the Seattle trials, swelling and joint pain, typical growth hormone side effects, were "very uncommon." Seattle report, 2001
Is it approved?
No approved version exists in the US today, or anywhere this guide could check. No FDA approval ever covered treating adults, or anti-aging.
- United States: approved in 1990 as a pituitary test and in 1997 to treat children. At the maker's request, FDA withdrew both approvals in 2009. In 2013 it found neither was withdrawn for safety or effectiveness reasons, so a generic copy could be approved. As of September 22, 2026, none has been. Federal Register, 2013 · Drugs@FDA
- Pharmacies: US rules let pharmacies compound with an ingredient of an FDA-approved drug, under set conditions. FDA's page does not say whether sermorelin still counts now its approvals are gone. It is not on FDA's nominated-substance list, and this guide found no FDA statement on it. FDA rules · FDA list, 2026
- Ireland: a pituitary test, Geref 50, was authorised in 1991 and withdrawn in 2007. Nothing with sermorelin is on the current list. Withdrawn list · Current list
- Europe: no sermorelin product on the European Medicines Agency's central list. Single EU countries were not checked. EMA data, 2026
- UK, Australia and elsewhere: not checked. Their regulators' databases could not be searched.
- Sport: banned at all times on the 2026 anti-doping list. WADA list, via JADCO
What is still unknown
- How tall treated children ended up. Review, 1999
- Any real-life result in adults: falls, fractures, frailty, disease or death. Review, 2003
- Whether muscle and fat really change. One trial found no change; another's gains were preliminary. Metabolism, 1997 · Seattle report, 2001
- Long-term safety, including cancer. No adult study here ran past 6 months, and no long-term animal cancer studies were done. US label
- What the antibodies mean over years. Acta Paediatrica, 1993
- Whether the thinking-test result holds up. No source here repeated it with sermorelin. Neurobiol Aging, 2006
What is in the bottle is not what was studied
One more thing.
The sermorelin trials on this page used pharmaceutical-grade drug. The Seattle trials, for one, used Serono's own Geref. Seattle report, 2001
No study has ever shown that a product sold online as "sermorelin" is the same thing. Not the same purity. Not the same strength. Not even proof it is the same molecule. Nothing sold online has been tested against what these studies used.
Pharmacy-made versions are not FDA-approved either. FDA does not check their safety, effectiveness or quality before they are sold. FDA
So take every number on this page for what it is. It describes the drug-grade sermorelin used in the trials. It describes nothing else.
How to check a number yourself
You are going to see more claims about sermorelin. In a reel. In a comment. On somebody's store page.
Here is how to tell a real one from a marketing one. Five questions. About ten seconds each.
1. Is there a link to a study?
A real number comes from a paper you can open. No link means it is a claim, not a result. Search pubmed.gov yourself, under the names papers use too: GHRH(1-29), GRF(1-29) and Geref. If nothing comes back, nothing was published.
2. Was it actually sermorelin?
On this page alone, results came from a close relative, full-length GHRH, mice missing the GHRH gene, and sermorelin mixed with two other peptides. A result for one of those is not a result for sermorelin.
3. Did it measure the thing being claimed?
Most adult studies measured hormones in blood. A higher IGF-1 is a blood test, not a stronger body or a longer life.
4. Was there a group that got nothing?
The fake shot is the whole point. The biggest children's study had none. The 14-day adult study compared older men with young men instead. Without that group, nobody can tell how much of the change was the drug.
5. Who was it approved for?
An approval covers one use in one group of people. Sermorelin's covered a pituitary test and children who lacked growth hormone. It never covered adults, and today even that is gone.
Now run those five on this page
Every number above links to the paper it came from. The chart says plainly it had no comparison group. The studies that did not use sermorelin are named, and so are the countries nobody could check.
The big adult claims — anti-aging, better sleep, longer life — have no study showing them in people. For sleep and lifespan, the closest evidence points the other way.
That is the whole difference: a number you can check, and a number you are asked to believe.
This page has a date on it, near the top. If a new human study of sermorelin is published, this page changes.
Read the studies yourself
- Children who lacked growth hormone, JCEM 1996 — the main one
- Review, 1999 — what it is, and the open question on adult height
- Against growth hormone: 60 children, 1993 · 43 children, 1993 · 9 children, 1997 · 7 children, 1989
- Fading: nonstop infusion, 1993 · short children, 1994 · growth hormone brake, 1987 · lab cells, 2001
- Older adults: 14 days, 1992 · 6 weeks, 1997 · Seattle trials, 2001 (free to read) · thinking tests, 2006 · Seattle review, 2003
- Not sermorelin alone: close relative, 1997 · three-peptide mix, 2017
- Animals and cells: mice without GHRH, 2013 · GHRH blocker, 2010 · prostate cells, 2022
- Labels: US label, via RxList · Irish label
- US status: Federal Register, 2013 · Drugs@FDA · compounding rules · nominated list · FDA on compounding
- Elsewhere: Ireland, withdrawn · Ireland, current · EMA data · WADA 2026 list, via JADCO
Everything above describes what studies gave to enrolled children and adults, or to lab animals and cells. This is not advice, a plan, or instructions. No sermorelin product is approved in the US today, and no FDA approval ever covered treating adults. Research compounds are not for human or animal use.